Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer
16 nov. 2023 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update
02 nov. 2023 07h00 HE
|
Chimerix, Inc.
– Phase 3 ACTION Study Ongoing with 113 Sites Activated Across 12 Countries; Interim Survival and PFS Data on Track to Report in 2025 – – Actively Recruiting ONC206 Dose Escalation Studies;...
Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023
26 oct. 2023 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix to Participate in Upcoming Investor Conferences
05 sept. 2023 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"
16 août 2023 10h05 HE
|
Chimerix, Inc.
Patients Treated with ONC201 Demonstrated Median Overall Survival (mOS) of 21.7 Months in the Front-Line Setting, Post Radiation, Versus 12 Months mOS Historical Control ONC201 Treatment Disrupts...
Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update
03 août 2023 07h00 HE
|
Chimerix, Inc.
– Phase 3 ACTION Study Ongoing with 77 Sites Activated Across 11 Countries; Reiterate First Interim Overall Survival Analysis Expected Early 2025 – – ONC206 Dose Escalation Completion Expected in...
Chimerix to Report Second Quarter 2023 Financial Results and Provide an Operational Update on August 3, 2023
27 juil. 2023 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., July 27, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Announces Promotion of Michael T. Andriole to President and Chief Executive Officer
27 juin 2023 16h05 HE
|
Chimerix, Inc.
Mike Sherman to Transition to Chair of the Board of Directors Martha Demski to Assume Role of Lead Independent Director DURHAM, N.C., June 27, 2023 (GLOBE NEWSWIRE) -- Chimerix,...
Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference
31 mai 2023 16h01 HE
|
Chimerix, Inc.
DURHAM, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix to Participate in Cancer Moonshot Brain Cancers Forum on Glioblastoma (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG) at White House
25 mai 2023 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., May 25, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...